Eli Lilly's weight loss drug slashes the risk of developing diabetes in long-term trial
The late-stage trial on tirzepatide also found that patients experienced sustained weight loss over the roughly three-year treatment period.
The late-stage trial on tirzepatide also found that patients experienced sustained weight loss over the roughly three-year treatment period.
